Armexa, a cybersecurity company that specializes in helping industrial organizations achieve secure, safe, reliable, and compliant operations, today announced that John Cusimano, Vice President of ...

Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Penelope Giraud will be taking over the role and leading the strategic direction of the Neutrogena, Aveeno and Dr. Ci Labo brands within the regions. As chief brand officer, Palmer will serve as a ...

Kenvue Inc. has named Penelope Giraud, President of Skin Health & Beauty for Asia Pacific and Latin America, leading the strategic direction of its portfolio of brands, including Neutrogena, Aveeno, ...

L’Oréal veteran Penelope Giraud will lead the direction of the company’s beauty brands Neutrogena, Aveeno and Dr. Ci Labo in the region Kenvue has appointed former L’Oréal executive Penelope Giraud as ...

Kenvue has introduced a ready-to-drink version of a WHO-approved oral rehydration solution (ORS) to address dehydration from diarrhea. This new format ensures accurate osmolarity, is convenient for ...

With the youngest baby boomers (Americans born between 1946 and 1964) approaching retirement age, it’s becoming increasingly important to focus on magnificent dividend stocks that will supply ...

(Image: ORS) Kenvue has introduced a Ready-to-Drink (RTD) version of WHO-approved Oral Rehydration Solution (ORS) for diarrhea-related dehydration. The product aims to provide an accurate ...

UBS lowered the firm’s price target on Kenvue (KVUE) to $23 from $24 and keeps a Neutral rating on the shares. Sentiment around Consumer Staples is as bearish despite underperforming the broader ...

SKILLMAN, N.J., January 16, 2025--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue’s common ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Kenvue (NYSE:KVUE) in the last three months. The table below summarizes their recent ratings ...